Key result
High-sensitivity cardiac troponin T elevation in non-ischemic conditions, including hypertension and chronic kidney disease, is associated with increased mortality and adverse cardiovascular events.
Why the study?
Hs-cTnT analyses are generally related to ischemia in the literature, prompting an evaluation of hs-cTnT in non-coronary patients.
High-sensitivity troponin T is a valuable prognostic biomarker for detecting subclinical myocardial damage and predicting adverse outcomes in patients without acute coronary syndrome.
Cardiac troponin is the preferred biomarker for the diagnosis of the acute coronary syndrome (ACS), but many other diseases can be identified with elevated troponin levels in the absence of ACS. The recent development of a high-sensitive cardiac troponin T (hs-cTnT) assay permits the detection of very low levels of cTnT. The use of hs-cTnT assay has emerged as a tool for identifying high-risk individuals for primary preventive treatment and can detect subclinical injury in asymptomatic patients. Hs-cTnT analyses are generally related to ischemia in the literature. Thus, we made an evaluation of hs-cTnT analysis in non-coronary patients, which may contribute to the literature.
No takes yet. Share an insight, caveat, or question.
Lütfü Aşkın (2019) conducted a review in Non-coronary artery disease conditions (Hypertension, Pulmonary Artery Hypertension, Chronic Kidney Disease, Cerebral Diseases). High-sensitivity cardiac troponin T (hs-cTnT) testing was evaluated. High-sensitivity cardiac troponin T elevation in non-ischemic conditions, including hypertension and chronic kidney disease, is associated with increased mortality and adverse cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: